KR100666016B1 - 테스토스테론 운데카노에이트 및 피마자유를 포함하는 제제 - Google Patents

테스토스테론 운데카노에이트 및 피마자유를 포함하는 제제 Download PDF

Info

Publication number
KR100666016B1
KR100666016B1 KR1020017012498A KR20017012498A KR100666016B1 KR 100666016 B1 KR100666016 B1 KR 100666016B1 KR 1020017012498 A KR1020017012498 A KR 1020017012498A KR 20017012498 A KR20017012498 A KR 20017012498A KR 100666016 B1 KR100666016 B1 KR 100666016B1
Authority
KR
South Korea
Prior art keywords
castor oil
liquid carrier
formulation
pharmaceutical formulation
undecanoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020017012498A
Other languages
English (en)
Korean (ko)
Other versions
KR20010108435A (ko
Inventor
니즈스데헨릭
챈들러수잔
페리엘리자베스앤
페르디난도조세핀존크리스틴
Original Assignee
악조 노벨 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 악조 노벨 엔.브이. filed Critical 악조 노벨 엔.브이.
Publication of KR20010108435A publication Critical patent/KR20010108435A/ko
Application granted granted Critical
Publication of KR100666016B1 publication Critical patent/KR100666016B1/ko
Assigned to 엔.브이.오가논 reassignment 엔.브이.오가논 권리의 전부이전등록 Assignors: 악조 노벨 엔.브이.
Assigned to 엠에스디 오스 비.브이. reassignment 엠에스디 오스 비.브이. 권리의 전부이전등록 Assignors: 엔.브이.오가논
Assigned to 머크 샤프 앤 도메 비.브이. reassignment 머크 샤프 앤 도메 비.브이. 권리의 전부이전등록 Assignors: 엠에스디 오스 비.브이.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
KR1020017012498A 1999-04-01 2000-03-27 테스토스테론 운데카노에이트 및 피마자유를 포함하는 제제 Expired - Lifetime KR100666016B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99302581.6 1999-04-01
EP99302581 1999-04-01

Publications (2)

Publication Number Publication Date
KR20010108435A KR20010108435A (ko) 2001-12-07
KR100666016B1 true KR100666016B1 (ko) 2007-01-10

Family

ID=8241306

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017012498A Expired - Lifetime KR100666016B1 (ko) 1999-04-01 2000-03-27 테스토스테론 운데카노에이트 및 피마자유를 포함하는 제제

Country Status (26)

Country Link
EP (1) EP1189620B1 (enExample)
JP (1) JP2002541111A (enExample)
KR (1) KR100666016B1 (enExample)
CN (1) CN1155385C (enExample)
AT (1) ATE269708T1 (enExample)
AU (1) AU768537B2 (enExample)
BR (1) BR0009465A (enExample)
CA (1) CA2366856C (enExample)
CZ (1) CZ298573B6 (enExample)
DE (1) DE60011771T2 (enExample)
DK (1) DK1189620T3 (enExample)
ES (1) ES2222199T3 (enExample)
HU (1) HU229455B1 (enExample)
ID (1) ID30481A (enExample)
IL (2) IL145524A0 (enExample)
MX (1) MXPA01009919A (enExample)
NO (1) NO329420B1 (enExample)
NZ (1) NZ514290A (enExample)
PL (1) PL195163B1 (enExample)
PT (1) PT1189620E (enExample)
RU (1) RU2246296C2 (enExample)
SK (1) SK286071B6 (enExample)
TR (1) TR200102769T2 (enExample)
TW (1) TWI280124B (enExample)
WO (1) WO2000059512A1 (enExample)
ZA (1) ZA200107781B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
JO2505B1 (en) 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
ES2258694T3 (es) * 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
US8241664B2 (en) 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
DK2068825T3 (da) 2006-10-04 2011-05-16 M & P Patent Ag Kontrolleret frisætningstilførselssystem til nasal påføring af neurotransmittere
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2011129812A1 (en) * 2010-04-12 2011-10-20 Clarus Therapeutics, Inc. Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
AU2012209184B2 (en) * 2011-01-26 2017-06-15 Allergan, Inc. Androgen composition for treating an opthalmic condition
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
WO2015193224A1 (en) 2014-06-17 2015-12-23 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
KR102397569B1 (ko) * 2014-06-19 2022-05-12 솔루랄 파마 에이피에스 친유성 화합물의 고형 경구 투여 형태
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
CN106999558A (zh) * 2014-08-29 2017-08-01 来普卡公司 (17‑β)‑3‑氧雄甾‑4‑烯‑17‑基十一酸酯组合物及其制备方法和用途
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
EP3824296B1 (en) 2018-07-20 2026-04-01 Lipocine Inc. Oral pharmaceutical composition comprising testosterone tridecanoate and/or testosterone dodecanoate for treating liver diseases
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9415810D0 (en) * 1994-08-04 1994-09-28 Jerrow Mohammad A Z Composition
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) * 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet

Also Published As

Publication number Publication date
NZ514290A (en) 2003-08-29
BR0009465A (pt) 2002-01-08
NO329420B1 (no) 2010-10-18
PL195163B1 (pl) 2007-08-31
PT1189620E (pt) 2004-10-29
DK1189620T3 (da) 2004-08-16
HU229455B1 (en) 2013-12-30
CN1346274A (zh) 2002-04-24
SK13722001A3 (sk) 2002-02-05
JP2002541111A (ja) 2002-12-03
ES2222199T3 (es) 2005-02-01
IL145524A (en) 2006-12-31
NO20014718L (no) 2001-09-28
HK1043544A1 (en) 2002-09-20
NO20014718D0 (no) 2001-09-28
TR200102769T2 (tr) 2002-05-21
CA2366856A1 (en) 2000-10-12
IL145524A0 (en) 2002-06-30
EP1189620B1 (en) 2004-06-23
AU4111100A (en) 2000-10-23
CZ20013507A3 (cs) 2002-03-13
HUP0200453A3 (en) 2003-06-30
ID30481A (id) 2001-12-13
RU2246296C2 (ru) 2005-02-20
CN1155385C (zh) 2004-06-30
PL351259A1 (en) 2003-04-07
HUP0200453A2 (hu) 2002-07-29
ZA200107781B (en) 2002-12-20
CA2366856C (en) 2006-05-16
TWI280124B (en) 2007-05-01
DE60011771T2 (de) 2004-11-04
KR20010108435A (ko) 2001-12-07
CZ298573B6 (cs) 2007-11-14
MXPA01009919A (es) 2002-04-24
EP1189620A1 (en) 2002-03-27
SK286071B6 (sk) 2008-02-05
DE60011771D1 (de) 2004-07-29
AU768537B2 (en) 2003-12-18
ATE269708T1 (de) 2004-07-15
WO2000059512A1 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
EP1189620B1 (en) Formulation comprising testosteron undecanoate and castor oil
US11331325B2 (en) Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
JP2002541111A5 (enExample)
EP0904064B1 (en) Oral pharmaceutical compositions containing sex hormones
US20050287203A1 (en) Formulation comprising testosteron undecanoate and castor oil
HK1043544B (en) Formulation comprising testosteron undecanoate and castor oil

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20010928

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20050228

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060706

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20061211

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20070102

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20070103

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20091224

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20101224

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20111228

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20121227

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20121227

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20131227

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20131227

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20141230

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20141230

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20151230

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20151230

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20161229

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20161229

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20171228

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20171228

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20181227

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20181227

Start annual number: 13

End annual number: 13

PC1801 Expiration of term

Termination date: 20200927

Termination category: Expiration of duration